Properties of the adeno-associated virus assembly-activating protein

Journal of Virology

Volumn 86, Issue 23, 2012, Pages 13038-13048

  Naumer, Matthias ^a,c   Sonntag, Florian ^a,d   Schmidt, Kristin ^a   Nieto, Karen ^a   Panke, Christian ^a,e   Davey, Norman E ^b   Popa Wagner, Ruth ^a   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c ABBOTT GMBH AND CO KG   (Germany)

^d Rentschler Biotechnologie GmbH   (Germany)

^e ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; ASSEMBLY ACTIVATING PROTEIN; PROTEIN VP3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DELETION MUTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC CONSERVATION; MUTATIONAL ANALYSIS; NONHUMAN; OLIGOMERIZATION; PLASMID; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; START CODON; TRANSLATION INITIATION; VIRUS ASSEMBLY; VIRUS CAPSID;

ANTIBODIES, MONOCLONAL; CAPSID; CAPSID PROTEINS; DEPENDOVIRUS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICROSCOPY, ELECTRON; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, DNA; VIRUS ASSEMBLY;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 84869208042     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01675-12     Document Type: Article

References (27)

1. Agbandje-McKenna M, Kleinschmidt J. 2011. AAV capsid structure and cell interactions. Methods Mol. Biol. 807:47-92.
2. Bevington JM, et al. 2007. Adeno-associated virus interactions with B23/ nucleophosmin: identification of sub-nucleolar virion regions. Virology 357:102-113.
3. Bleker S, Sonntag F, Kleinschmidt JA. 2005. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79:2528-2540.
4. Caspar DL. 1980. Movement and self-control in protein assemblies. Quasi-equivalence revisited. Biophys. J. 32:103-138.
5. Cole C, Barber JD, Barton GJ. 2008. The Jpred 3 secondary structure prediction server. Nucleic Acids Res. 36:W197-W201.
6. DiPrimio N, Asokan A, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2008. Surface loop dynamics in adeno-associated virus capsid assembly. J. Virol. 82:5178-5189.
7. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792-1797.
8. Erickson HP, Pantaloni D. 1981. The role of subunit entropy in cooperative assembly. Nucleation of microtubules and other two-dimensional polymers. Biophys. J. 34:293-309.
9. Fane BA, Prevelige PE, Jr. 2003. Mechanism of scaffolding-assisted viral assembly. Adv. Protein Chem. 64:259-299.
10. Gao G, Vandenberghe LH, Wilson JM. 2005. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5:285-297.
11. Grimm D, et al. 1999. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6:1322-1330.
12. Kleinschmidt JA, King JA. 2006. Molecular interactions involved in assembling the viral particle and packaging the genome, p 305-319. In Kerr J, Cotmore SF, Bloom ME, Linden RM, Parrish CR (ed), Parvoviruses. Hodder Arnold, New York, NY.
13. Kuck D, Kern A, Kleinschmidt JA. 2007. Development of AAV serotypespecific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140: 17-24.
14. McCraw DM, O'Donnell JK, Taylor KA, Stagg SM, Chapman MS. 2012. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 431:40-49.
15. Muzyczka N, Berns KI. 2001. Parvoviridae: the viruses and their replication, p 2327-2360. In Knipe DM, et al (ed) Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
16. Myers MW, Carter BJ. 1980. Assembly of adeno-associated virus. Virology 102:71-82.
17. Naldini L, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
18. Popa-Wagner R, Sonntag F, Schmidt K, King J, Kleinschmidt JA. 2012. Nuclear translocation of AAV2 capsid proteins for virion assembly. J. Gen. Virol. 93:1887-1898.
19. Ruffing M, Heid H, Kleinschmidt JA. 1994. Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif. J. Gen. Virol. 75:3385-3392.
20. Sonntag F, et al. 2011. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol. 85:12686-12697.
21. Sonntag F, Schmidt K, Kleinschmidt JA. 2010. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. U. S. A. 107:10220-10225.
22. Ward P. 2006. Replication of adeno-associated virus DNA, p 189-212. In Kerr J, Cotmore SF, Bloom ME, Linden RM, Parrish CR (ed), Parvoviruses. Hodder Arnold, New York, NY.
23. Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. 1997. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71:1341-1352.
24. Wistuba A, Weger S, Kern A, Kleinschmidt JA. 1995. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69:5311-5319.
25. Wobus CE, et al. 2000. Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74:9281-9293.
26. Wu P, et al. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-8647.
27. Xie Q, et al. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99: 10405-10410.